Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study

Journal of Thrombosis and Haemostasis : JTH
K P CohoonTheodore E Spiro

Abstract

Essentials Net benefit of venous thromboprophylaxis (VTE) in patients hospitalized for infections is unknown. MAGELLAN trial subgroup analysis was performed for patients hospitalized for acute infectious diseases. At day 35, prolonged rivaroxaban prophylaxis reduced VTE compared to enoxaparin (4.2% vs. 6.6%). Rivaroxaban prophylaxis reduced VTE in patients hospitalized for active lung infections. Background Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases. Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days. Patients/Methods A subgroup analysis of patients hospitalized for acute infectious diseases in the MAGELLAN trial was performed. The primary efficacy outcome was the composite of asymptomatic proximal or symptomatic VTE at days 10 and 35. The principal safety outcome was the composite of major or clinically relevant non-major bleeding. Results Three thousand one hundred and seventy-three patients with ...Continue Reading

References

Jun 1, 2002·Archives of Internal Medicine·John A HeitL Joseph Melton
Dec 31, 2003·Thrombosis Research·Johanna S UngerstedtMargareta Blombäck
Apr 30, 2004·Statistics in Medicine·Michael J SweetingPaul C Lambert
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Nov 12, 2005·British Journal of Haematology·Charles T Esmon
Feb 26, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·John A Heit
Aug 20, 2009·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Eman MosadAzza A Eltayeb
Jan 30, 2010·Critical Care Medicine·Marcel Levi, Tom van der Poll
Aug 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Tobias A FuchsDenisa D Wagner
Mar 2, 2011·Journal of Thrombosis and Thrombolysis·Alexander Thomas CohenVictor Tapson
Oct 27, 2011·Journal of Internal Medicine·M SchmidtH T Sørensen
Nov 15, 2011·The New England Journal of Medicine·Samuel Z GoldhaberUNKNOWN ADOPT Trial Investigators
Mar 28, 2012·The Journal of Experimental Medicine·Marie-Luise von BrühlSteffen Massberg
Apr 5, 2012·Circulation·Mary A M RogersKenneth M Langa
Jun 2, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Tobias A FuchsDenisa D Wagner
Oct 30, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Maurits L van MontfoortSacha Zeerleder
Feb 8, 2013·The New England Journal of Medicine·Alexander T CohenUNKNOWN MAGELLAN Investigators
Mar 14, 2013·Expert Opinion on Medical Diagnostics·Dawn M Coleman, Thomas W Wakefield
Nov 5, 2013·Journal of Vascular Surgery. Venous and Lymphatic Disorders·J A DiazUNKNOWN for the Michigan Research Venous Group*
Mar 29, 2014·Journal of Thrombosis and Haemostasis : JTH·A S SavchenkoD D Wagner
May 13, 2014·The American Journal of Medicine·Wei HuangFrederick A Spencer
Mar 3, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yu-Guang ChenChia-Hung Kao
May 17, 2015·Blood·Julia EtulainDenisa D Wagner
Jul 26, 2016·Frontiers in Immunology·Andrew S KimballPeter K Henke
Oct 11, 2017·The American Journal of Medicine·Kevin P CohoonJohn A Heit

❮ Previous
Next ❯

Citations

Jul 3, 2020·Disaster Medicine and Public Health Preparedness·Alessandro CostaLuca Ragazzoni
Jul 1, 2020·Journal of Thrombosis and Thrombolysis·Chia Siang Kow, Syed Shahzad Hasan
May 28, 2020·Journal of Thrombosis and Haemostasis : JTH·Alex C SpyropoulosUNKNOWN Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the Int
Jun 17, 2020·Research and Practice in Thrombosis and Haemostasis·Kevin P CohoonAlex C Spyropoulos
Jun 23, 2020·Journal of Cardiovascular Pharmacology·Elizabeth M GavioliEtty Vider
Feb 7, 2021·Seminars in Respiratory and Critical Care Medicine·Kira MacDougall, Alex C Spyropoulos
Nov 14, 2020·Thrombosis and Haemostasis·Henny H BillettEran Bellin
Mar 19, 2021·Research and Practice in Thrombosis and Haemostasis·Alex C SpyropoulosUNKNOWN COVID‐19 Consortium Group
Aug 27, 2021·Clinical Practice and Cases in Emergency Medicine·Alexander W ArenaMiriam L Kulkarni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

The New England Journal of Medicine
Alexander T CohenAPEX Investigators
Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Eduardo RamacciottiGilson Roberto Araujo
The New England Journal of Medicine
David R AndersonPascal-Andre Vendittoli
© 2022 Meta ULC. All rights reserved